Tag: First-line mPAC treatment

Home / First-line mPAC treatment

Categories

Irinotecan liposome is approved by the USFDA for first-line treatment of metastatic pancreatic adenocarcinoma

The Food and Drug Administration approved irinotecan liposome (Onivyde, Ipsen Biopharmaceuticals, Inc.) with oxaliplatin, fluorouracil, and leucovorin on February 13, 2024, for treating metastatic pa...
first-line-mpac-treatment

Scan the code